



## Aktuelle Publikationen

- 1. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.**  
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, **Gomez S**, Wust P, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).  
*Eur Urol.* 2021 Sep;80(3):306-315.
- 2. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.**  
Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcman G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, **Riesterer O**, Bouvier-Morel E, Dunant A, Edwards JG, Thomas PA, Mercier O, Bardet A.  
*Lancet Oncol.* 2021 Dec 14:S1470-2045.
- 3. Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.**  
Vuong D, Bogowicz M, Wee L, **Riesterer O**, Vlaskou Badra E, D'Cruz LA, Balermipas P, van Timmeren JE, Burgermeister S, Dekker A, De Ruyscher D, Unkelbach J, Thierstein S, Eboulet EI, Peters S, Pless M, Guckenberger M, Tanadini-Lang S.  
*Sci Rep.* 2021 Oct 22;11(1):20890.
- 4. Five fraction stereotactic radiotherapy after brain metastasectomy: a single-institution experience and literature review.**  
**Rogers S**, Stauffer A, **Lomax N**, **Alonso S**, **Eberle B**, **Gomez Ordoñez S**, **Lazeroms T**, **Kessler E**, **Brendel M**, Schwyzer L, **Riesterer O**.  
*J Neurooncol.* 2021 Oct;155(1):35-43.
- 5. Successful salvage of recurrent leptomeningeal disease in large cell neuroendocrine lung cancer with stereotactic radiotherapy.**  
**Lee SY**, **Lomax N**, Berkmann S, Vollmer K, **Riesterer O**, **Bodis S**, **Rogers S**.  
*Strahlenther Onkol.* 2021 Dec;197(12):1143-1147.
- 6. Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes.**  
Bogowicz M, Pavic M, **Riesterer O**, Finazzi T, Garcia Schüler H, Holz-Sapra E, Rudofsky L, Basler L, Spaniol M, Ambrusch A, Hüllner M, Guckenberger M, Tanadini-Lang S.  
*Front Oncol.* 2021 May 27;11:664304.
- 7. Quantification of thermal dose in moderate clinical hyperthermia with radiotherapy: a relook using temperature-time area under the curve (AUC).**  
**Datta NR**, **Marder D**, **Datta S**, **Meister A**, **Puric E**, **Stutz E**, **Rogers S**, **Eberle B**, **Timm O**, **Staruch M**, **Riesterer O**, **Bodis S**.  
*Int J Hyperthermia.* 2021;38(1):296-307.



8. **The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas.**  
**Rogers SJ, Datta NR, Puric E, Timm O, Marder D, Khan S, Mamot C, Knuchel J, Siebenhüner A, Pestalozzi B, Guckenberger M, Bodis S, Riesterer O.**  
*Clin Transl Radiat Oncol.* 2021 Jan 25;27:109-113.
9. **NTCP Modeling of Late Effects for Head and Neck Cancer: A Systematic Review.**  
**Stieb S, Lee A, van Dijk LV, Frank S, Fuller CD, Blanchard P.**  
*Int J Part Ther.* 2021 Jun 25;8(1):95-107. doi: 10.14338/20-00092. eCollection 2021 Summer.
10. **<sup>18</sup>FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer.**  
Elhalawani H, Cardenas CE, Volpe S, Barua S, **Stieb S**, Rock CB, Lin T, Yang P, Wu H, Zaveri J, Elgohari B, Abdallah LE, Jethanandani A, Mohamed ASR, Court LE, Hutcheson KA, Brandon Gunn G, Rosenthal DI, Frank SJ, Garden AS, Rao A, Fuller CD.  
*Clin Transl Radiat Oncol.* 2021 Jun 6;29:93-101. doi: 10.1016/j.ctro.2021.05.011. eCollection 2021 Jul.
11. **Development and validation of a contouring guideline for the taste bud bearing tongue mucosa.**  
**Stieb S, Mohamed ASR, He R, Zhu LL, McDonald BA, Wahid K, van Dijk LV, Ventura J, Ahmed S, McCoy L, Deshpande TS, Grant S, Reddy JP, Phan J, Garden AS, Rosenthal DI, Frank SJ, Gunn GB, Fuller CD.**  
*Radiother Oncol.* 2021 Apr;157:63-69.
12. **Prospective Evaluation of Changes in Pain Levels, Quality of Life and Functionality After Low Dose Radiotherapy for Epicondylitis, Plantar Fasciitis, and Finger Osteoarthritis.**  
**Rogers S, Eberle B, Vogt DR, Meier E, Moser L, Gomez Ordoñez S, Desborough S, Riesterer O, Takacs I, Hasler P, Bodis S.** Prospective Evaluation of Changes in Pain Levels, Quality of Life and Functionality After Low Dose Radiotherapy for Epicondylitis, Plantar Fasciitis, and Finger Osteoarthritis.  
*Front Med (Lausanne).* 2020 May 19;7:195; doi: 10.3389/fmed.2020.00195.
13. **Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses.**  
**Datta NR, Kok HP, Crezee H, Gaipl US, Bodis S.**  
*Front Oncol.* 2020 Jun 12; doi: 10.3389/fonc.2020.00819.
14. **Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.**  
**Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G**  
*Radiother Oncol.* 2020 Jun; DOI: 10.1016/j.radonc.2020.06.011.
15. **Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer.**  
Bogowicz M, Jochems A, Deist TM, Tanadini-Lang S, Huang SH, Chan B, Waldron JN, Bratman S, O'Sullivan B, **Riesterer O**, Studer G, Unkelbach J, Barakat S, Brakenhoff RH, Nauta I, Gazzani SE, Calareso G, Scheckenbach K, Hoebbers F, Wesseling FWR, Keek S, Sanduleanu S, Leijenaar RTH, Vergeer MR, Leemans CR, Terhaard CHJ, van den Brekel MWM, Hamming-Vriese O, van der Heijden MA, Elhalawani HM, Fuller CD, Guckenberger M, Lambin P.  
*Sci Rep.* 2020 Mar 11;10(1); DOI: 10.1038/s41598-020-61297-4.



- 16. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma.**  
Galiza Barbosa F, **Riesterer O**, Tanadini-Lang S, **Stieb S**, Studer G, Pruschy M, Huber GF, Huellner MW, Stolzmann P, Veit-Haibach P.  
*Head Neck*. 2020 Feb;42(2):163-170.; DOI: 10.1002/hed.25975.
- 17. A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives.**  
Achard V, Aebersold DM, Allal AS, Andratschke N, Baumert BG, Beer KT, Betz M, Breuneval T, **Bodis S**, de Bari B, Förster R, Franzetti-Pellanda A, Guckenberger M, Herrmann E, Huck, Khanfir D, Matzinger O, Peguret ON, Pesce G, Putora PM, Reuter C, Richetti A, Veas H, Vrieling C, Zaugg K, Zimmermann F, Zwahlen DR, Tsoutsou P, Zilli T.  
*Radiother Oncol*, 2020 Sep. DOI: 10.1016/j.radonc.2020.05.047.
- 18. Radiomic biomarkers for head and neck squamous cell carcinoma.**  
Tanadini-Lang S, Balermipas P, Guckenberger M, Pavic M, **Riesterer O**, Vuong D, Bogowicz M.  
*Strahlenther Onkol*. 2020 Jun. DOI: 10.1007/s00066-020-01638-4.
- 19. Strategies to maximize available resources with minimum cost escalation for improving radiotherapy accessibility in the post COVID-19 era : An analysis for Asia.**  
**Datta N R**, Datta S, Samiei M.  
*Adv Radiat Oncol*. 2020 Sep. DOI: 10.1016/j.adro.2020.09.005.
- 20. Early results and volumetric analysis after spot-scanning proton therapy with concomitant hyperthermia in large inoperable sacral chordomas.**  
Tran S, **Puric E**, Walser M, Poel R, **Datta N R**, **Heuberger J**, Pica A, **Marder D**, **Lomax N**, Bolsi A, Morach P, Bachtary B, Seddon B M, Schneider R, **Bodis S** and Weber D C  
*BJR*. 2020 Mar; doi.org/10.1259/bjr.20180883 .
- 21. Reduced and standard field-of-view diffusion weighted imaging in patients with rectal cancer at 3 T-Comparison of image quality and apparent diffusion coefficient measurements.** Attenberger UI, Tavakoli A, Stocker D, **Stieb S**, **Riesterer O**, Turina M, Schoenberg SO, Pilz L, Reiner CS.  
*Eur J Radiol*. 2020 Oct;131:109257. doi: 10.1016/j.ejrad.2020.109257. Epub 2020 Sep 6. PMID: 32947092.
- 22. Klinischer Einsatz der Hyperthermie in der Therapie von malignen Beckentumoren,** **Puric E**, Stutz E, Lindner L, **Meister A**, **Kern T**, **Datta N**, **Rogers S**, **Riesterer O**.  
*InFo Hämatologie + Onkologie* 23(7-8):35-44 (August 2020).
- 23. Stellenwert der Radio(chemo)therapie bei Pankreas- und hepatobiliären Karzinomen.** **Riesterer O**.  
*Schweizer Krebsbulletin*. 2020 Feb.